Logo image of BXRX

BAUDAX BIO INC (BXRX) Stock Fundamental Analysis

NASDAQ:BXRX - Nasdaq - US07160F4046 - Common Stock - Currency: USD

0.1864  +0 (+0.59%)

After market: 0.17 -0.02 (-8.8%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BXRX. BXRX was compared to 193 industry peers in the Pharmaceuticals industry. BXRX has a bad profitability rating. Also its financial health evaluation is rather negative. BXRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BXRX had negative earnings in the past year.
In the past year BXRX has reported a negative cash flow from operations.
BXRX had negative earnings in each of the past 5 years.
In the past 5 years BXRX always reported negative operating cash flow.
BXRX Yearly Net Income VS EBIT VS OCF VS FCFBXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -161.54%, BXRX is doing worse than 88.35% of the companies in the same industry.
Industry RankSector Rank
ROA -161.54%
ROE N/A
ROIC N/A
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BXRX Yearly ROA, ROE, ROICBXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

BXRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BXRX Yearly Profit, Operating, Gross MarginsBXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

BXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BXRX has more shares outstanding than it did 1 year ago.
BXRX has a worse debt/assets ratio than last year.
BXRX Yearly Shares OutstandingBXRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
BXRX Yearly Total Debt VS Total AssetsBXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -17.15, we must say that BXRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.15, BXRX is doing worse than 86.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.15
ROIC/WACCN/A
WACC6.12%
BXRX Yearly LT Debt VS Equity VS FCFBXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M

2.3 Liquidity

A Current Ratio of 0.09 indicates that BXRX may have some problems paying its short term obligations.
BXRX has a worse Current ratio (0.09) than 99.03% of its industry peers.
A Quick Ratio of 0.09 indicates that BXRX may have some problems paying its short term obligations.
The Quick ratio of BXRX (0.09) is worse than 99.03% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
BXRX Yearly Current Assets VS Current LiabilitesBXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.23% over the past year.
The Revenue for BXRX has decreased by -19.12% in the past year. This is quite bad
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.89% on average over the next years. This is quite good.
The Revenue is expected to grow by 149.06% on average over the next years. This is a very strong growth
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%

3.3 Evolution

BXRX Yearly Revenue VS EstimatesBXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
BXRX Yearly EPS VS EstimatesBXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BXRX Price Earnings VS Forward Price EarningsBXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BXRX Per share dataBXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as BXRX's earnings are expected to grow with 25.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y25.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAUDAX BIO INC

NASDAQ:BXRX (11/15/2023, 8:21:44 PM)

After market: 0.17 -0.02 (-8.8%)

0.1864

+0 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2023-11-14/bmo
Earnings (Next)02-21 2024-02-21/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners8.97%
Ins Owner Change0%
Market Cap1.71M
Analysts43.33
Price Target24.48 (13033.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.86%
Min EPS beat(2)-166.67%
Max EPS beat(2)26.95%
EPS beat(4)1
Avg EPS beat(4)-46.41%
Min EPS beat(4)-166.67%
Max EPS beat(4)26.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-71.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-44.16
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.06
BVpS-0.18
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -17.15
F-Score3
WACC6.12%
ROIC/WACCN/A
Cap/Depr(3y)11%
Cap/Depr(5y)240.77%
Cap/Sales(3y)50.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%
EBIT growth 1Y-1230.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.75%
OCF growth 3YN/A
OCF growth 5YN/A